Nair Jayasree, Vali Payam, Gugino Sylvia F, Koenigsknecht Carmon, Helman Justin, Nielsen Lori C, Chandrasekharan Praveen, Rawat Munmun, Berkelhamer Sara, Mathew Bobby, Lakshminrusimha Satyan
Department of Pediatrics, University at Buffalo, The State University of New York, Buffalo, NY, United States of America.
Department of Pediatrics, UC Davis School of Medicine, Sacramento, CA, United States of America.
Early Hum Dev. 2019 Mar;130:27-32. doi: 10.1016/j.earlhumdev.2019.01.006. Epub 2019 Jan 16.
Distressed infants in the delivery room and those that have completed postnatal transition are both resuscitated according to established neonatal resuscitation guidelines, often with endotracheal (ET) epinephrine at the same dose. We hypothesized that ET epinephrine would have higher bioavailability in a post-transitional compared to transitioning newborn model due to absence of fetal lung liquid and intra-cardiac shunts.
15 term fetal (transitioning newborn) and 6 postnatal lambs were asphyxiated by umbilical cord and ET tube occlusion respectively. Lambs were resuscitated after 5 min of asystole. ET epinephrine (0.1 mg/kg) was administered after 1 min of positive pressure ventilation (PPV) and chest compressions, and repeated 3 min later, followed by intravenous (IV) epinephrine (0.03 mg/kg) every 3 min until return of spontaneous circulation (ROSC). Serial plasma epinephrine concentrations were measured.
Peak plasma epinephrine concentrations were lower in transitioning newborns as compared to postnatal lambs: after a single ET dose (145.36 ± 135.5 ng/ml vs 553.54 ± 215 ng/ml, p < 0.01) and after two ET doses (443 ± 192.49 ng/ml vs 1406 ± 420.8 ng/ml, p < 0.01). The rates of ROSC with a single ET dose were similar in both groups (40% vs 50% in newborn and postnatal respectively, p > 0.99). There was a higher incidence of post-ROSC tachycardia and increased carotid blood flow in the postnatal group.
In the postnatal period, ET epinephrine at currently recommended doses resulted in higher peak epinephrine concentrations, post-ROSC tachycardia and cerebral reperfusion without significant differences in incidence of ROSC. Further studies evaluating the optimal dose of ET epinephrine during the postnatal period are warranted.
产房内情况危急的婴儿以及已完成出生后过渡的婴儿均按照既定的新生儿复苏指南进行复苏,通常使用相同剂量的气管内(ET)肾上腺素。我们推测,由于不存在胎儿肺液和心内分流,与处于过渡阶段的新生儿模型相比,ET肾上腺素在出生后过渡阶段的生物利用度会更高。
分别通过脐带和ET管阻塞使15只足月胎儿(处于过渡阶段的新生儿)和6只出生后的羔羊窒息。在心脏停搏5分钟后对羔羊进行复苏。在正压通气(PPV)和胸外按压1分钟后给予ET肾上腺素(0.1mg/kg),3分钟后重复给药,随后每3分钟静脉注射(IV)肾上腺素(0.03mg/kg),直至自主循环恢复(ROSC)。测量血浆肾上腺素浓度系列。
与出生后的羔羊相比,处于过渡阶段的新生儿的血浆肾上腺素峰值浓度较低:单次ET给药后(145.36±135.5ng/ml对553.54±215ng/ml,p<0.01)以及两次ET给药后(443±192.49ng/ml对1406±420.8ng/ml,p<0.01)。两组单次ET给药后的ROSC发生率相似(新生儿组和出生后组分别为40%对50%,p>0.99)。出生后组ROSC后心动过速的发生率更高,颈动脉血流量增加。
在出生后阶段,目前推荐剂量的ET肾上腺素导致更高的肾上腺素峰值浓度、ROSC后心动过速和脑再灌注,而ROSC发生率无显著差异。有必要进一步研究评估出生后阶段ET肾上腺素的最佳剂量。